[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-US2015/119385,2015,A1
[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/59668,2015,A1
[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2016/151501,2016,A1
[4]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2016/151500,2016,A1
[5]Fairhurst,RobinA.;Knoepfel,Thomas;Buschmann,Nicole;Leblanc,Catherine;Mah,Robert;Todorov,Milen;Nimsgern,Pierre;Ripoche,Sebastien;Niklaus,Michel;Warin,Nicolas;Luu,VanHuy;Madoerin,Mario;Wirth,Jasmin;Graus-Porta,Diana;Weiss,Andreas;Kiffe,Michael;Wartmann,Markus;Kinyamu-Akunda,Jacqueline;Sterker,Dario;Stamm,Christelle;Adler,Flavia;Buhles,Alexandra;Schadt,Heiko;Couttet,Philippe;Blank,Jutta;Galuba,Inga;Trappe,Jörg;Voshol,Johannes;Ostermann,Nils;Zou,Chao;Berghausen,Jörg;DelRioEspinola,Alberto;Jahnke,Wolfgang;Furet,Pascal[JournalofMedicinalChemistry,2020,vol.63,#21,p.12542-12573]
[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-US2015/119385,2015,A1
[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/59668,2015,A1
[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2016/151501,2016,A1
[4]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2016/151500,2016,A1
[5]Fairhurst,RobinA.;Knoepfel,Thomas;Buschmann,Nicole;Leblanc,Catherine;Mah,Robert;Todorov,Milen;Nimsgern,Pierre;Ripoche,Sebastien;Niklaus,Michel;Warin,Nicolas;Luu,VanHuy;Madoerin,Mario;Wirth,Jasmin;Graus-Porta,Diana;Weiss,Andreas;Kiffe,Michael;Wartmann,Markus;Kinyamu-Akunda,Jacqueline;Sterker,Dario;Stamm,Christelle;Adler,Flavia;Buhles,Alexandra;Schadt,Heiko;Couttet,Philippe;Blank,Jutta;Galuba,Inga;Trappe,Jörg;Voshol,Johannes;Ostermann,Nils;Zou,Chao;Berghausen,Jörg;DelRioEspinola,Alberto;Jahnke,Wolfgang;Furet,Pascal[JournalofMedicinalChemistry,2020,vol.63,#21,p.12542-12573]
[1]Patent:US2015/119385,2015,A1
[2]Patent:WO2015/59668,2015,A1
[3]Patent:WO2016/151501,2016,A1
[4]Patent:WO2016/151500,2016,A1
[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-US2015/119385,2015,A1
[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/59668,2015,A1
[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2016/151501,2016,A1
[4]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2016/151500,2016,A1
[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-US2015/119385,2015,A1
[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/59668,2015,A1
[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2016/151501,2016,A1
[4]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2016/151500,2016,A1
[5]Fairhurst,RobinA.;Knoepfel,Thomas;Buschmann,Nicole;Leblanc,Catherine;Mah,Robert;Todorov,Milen;Nimsgern,Pierre;Ripoche,Sebastien;Niklaus,Michel;Warin,Nicolas;Luu,VanHuy;Madoerin,Mario;Wirth,Jasmin;Graus-Porta,Diana;Weiss,Andreas;Kiffe,Michael;Wartmann,Markus;Kinyamu-Akunda,Jacqueline;Sterker,Dario;Stamm,Christelle;Adler,Flavia;Buhles,Alexandra;Schadt,Heiko;Couttet,Philippe;Blank,Jutta;Galuba,Inga;Trappe,Jörg;Voshol,Johannes;Ostermann,Nils;Zou,Chao;Berghausen,Jörg;DelRioEspinola,Alberto;Jahnke,Wolfgang;Furet,Pascal[JournalofMedicinalChemistry,2020,vol.63,#21,p.12542-12573]
Title: Nicole Buschmann, et al. Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. WO2015059668A1.
Title: Robin A Fairhurst, et al. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. J Med Chem. 2020 Nov 12;63(21):12542-12573.